Global Crohn's Disease Market – Industry Trends - Forecast to 2026

  • Pharmaceutical
  • Upcoming Report
  • May 2019
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Crohn's Disease Market By Procedures (Colonoscopy, Flexible Sigmoidoscopy, Computerized Tomography (CT), Magnetic Resonance Imaging (MRI), Capsule Endoscopy, Double-Balloon Endoscopy, Small Bowel Imaging), Therapeutic type {Non-surgical(Antibiotics, Anti-Diarrheal, Immune System Suppressors, Pain Relievers, Anti-Inflammatory Drugs), Surgical}, Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends & Forecast to 2026

Market Analysis: Global Crohn's Disease Market

Global Crohn's Disease Market is expected to rise gradually to an estimated value of USD 13.52 billion by 2026, registering a CAGR of 4.1% in the forecast period of 2019-2026 with the annual sales of USD 9.8 billion in the year 2018. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients.

Market Definition: Global Crohn's Disease Market

Crohn’s Disease is also called as inflammatory bowel disease (IBD), as it causes inflammation of the gastro-intestinal tract resulting into abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Crohn’s disease is a rare disease, caused by a combination of factors involving genetics, the environment, and an overactive immune system.

According to the CDC, 3 million people in US and are suffering from Crohn’s Disease in 2015. Almost more than half of these cases could have been avoided with the availability of proper medical equipment and devices for healthcare procedures. This significant number is expected to act as a driver to the market growth.

Market Drivers

  • High prevalence rate of the disease will drive the market.
  • Prompt diagnosis of the disease and individual treatment of each symptom of the IBD can help in the growth of the market.

Market Restraints

  • Lack of awareness about the available treatment options among the population that belongs to middle and low-income economies can hinder the market growth.
  • Biologics going off-patent can increase the biosimilar competition that can affect the growth of the market.

Segmentation: Global Crohn's Disease Market

By Procedures

  • Colonoscopy
  • Flexible Sigmoidoscopy
  • Computerized Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Capsule Endoscopy
  • Double-Balloon Endoscopy
  • Small Bowel Imaging

By Therapeutic Type

  • Non-surgical

    • Antibiotics
    • Anti-Diarrheal
    • Immune System Suppressors
    • Pain Relievers
    • Anti-Inflammatory Drugs

  • Surgical

By Geography

  • North America

    • U.S.
    • Canada
    • Mexico

  • South America

    • Brazil
    • Argentina
    • Rest of South America

  • Europe

    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe

  • Asia-Pacific

    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia Pacific

  • Middle East & Africa

    • South Africa
    • Egypt
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Rest of Middle East & Africa

Key Developments in the Market:

  • On 19th October, 2018, global pharmaceutical company, Mylan N.V. announced the commercial launch of Hulio™, a biosimilar to AbbVie's Humira® (adalimumab), across major markets in Europe. The product is approved by EU for all adalimumab indications and after the patent expiry it has the potential to capture Humira’s market
  • On 13th December 2017, Pfizer Inc. announced that the US-FDA has approved IXIFI™, a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade® (infliximab)* and it has the potential to capture the market shares of Remicade as the patent has expired.
  • In April 2016, the U.S. Food and Drug Administration (FDA) approved Inflectra (Celtrion, Inc.), a biosimilar to Remicade (Janssen Biotech, Inc.) for patients suffering from Crohn’s disease. This approval will provide patients some other alternatives and help in the growth of the Crohn’s disease market.

Competitive Analysis: Global Crohn's Disease Market

Global Crohn’s disease market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Crohn’s disease market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Competitors: Global Crohn's Disease Market

Few of the major competitors currently working in the Crohn’s disease market are AbbVie Inc. (US), Allergan, Inc. (US), Bayer AG (Germany), Bristol-Myers Squibb (US), Boehringer Ingelheim GmbH (Germany), F. Hoffmann-La Roche (Switzerland), Eli Lilly and Co. (US), GlaxoSmithKline plc (UK), Janssen Biotech, Inc. (US), Johnson & Johnson (US), Novartis International AG (Switzerland), Pfizer Inc. (US), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), UCB S.A. (Belgium), Ferring B.V. (Switzerland), Tillotts Pharma AG (Switzerland) and few among others.

Research Methodology: Global Crohn's Disease Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request an Analyst Call or can drop down your inquiry.

The key research methodology used by DBMR Research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

  • Current and future of global Crohn’s disease market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

SKU-

Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

CHOOSE LICENCE TYPE
  • 5400.00
  • 4200.00
BUY NOW ADD TO CART